Rapamycin (sirolimus) and longevity in Germany

Rapamycin (sirolimus) is a prescription immunosuppressant, a drug that dampens the immune system, and not a supplement. Rapamycin and sirolimus are two names for the same molecule. It comes from a soil bacterium called Streptomyces hygroscopicus, first found on Easter Island (Rapa Nui). The FDA approved it in 1999 as Rapamune,^[24] and the EU followed on 13 March 2001.^[6] Both times the goal was to stop the body from rejecting a transplanted kidney. Because it really does weaken the immune defence, any other use carries real risk, which is why this guide describes the evidence and gives no medical advice.

That immune effect comes from a single target, a protein switch called mTOR.^[1] It checks whether cells have plenty of nutrients, and rapamycin blocks above all one version of it, called mTORC1. The switch steers cell growth, the building of new proteins and autophagy, the way cells clear out their own worn-out parts.

The same switch is why the longevity scene pays attention, because mice lived longer even when rapamycin treatment began late in life, at 600 days of age.^[1] That result comes from the NIH Interventions Testing Program (ITP), which tests drugs in mice at three separate labs. The effect repeated at all three sites and in later ITP studies,^[1][11] which makes it one of the most consistent drug results in mouse lifespan research. That consistency in mice, rather than any result in people, is what turned a transplant drug into a longevity topic.

mTOR is the nutrient switch that tells cells whether to grow or to repair, and turning it down with rapamycin extends the lives of mice.^[1] The switch flips on when food is plentiful, and it also controls autophagy, the cell's clean-up. One leading idea is that constant mTOR activity holds back that clean-up and lets worn-out cells build up, which may help explain the mouse results. That link is not proven in people.

Turning the switch down does not help every animal, though. Blocking TOR, the same switch in simpler organisms, extends life in yeast, worms and flies,^[1] but the results vary with dose, diet, strain and sex. In fly experiments, rapamycin mostly shortened life on one yeast-based diet and did no harm on a richer one.^[25] Worms gave no clearer picture, because the effects were weak, sometimes hard to reproduce and harmful at the highest dose.^[26] Mice are the stronger case, although even there rapamycin and eating less extend life through partly different routes,^[11] so the drug is not a stand-in for fasting.

The mouse numbers come from two ITP studies that differ in when treatment started and in dose. They use three measures. The mean is the average lifespan, and the median is the age by which half the mice had died. The oldest 10% looks at the longest-lived tenth. Read each row as the gain over untreated mice of the same sex:

Source: Harrison et al., Nature 2009.^[1]; Miller et al., Aging Cell 2014, Table 1^[11]

The 14% figure that often circulates for females is the oldest-10% number from the late-start study, while the matching mean is 13%.^[1] Beyond that one cell, two patterns in the table carry more weight. The late-start effect held at all three ITP labs in a genetically mixed mouse stock,^[1] which makes it harder to dismiss than a single-lab result. In the 2014 study, a higher dose started earlier raised median lifespan further, but the gain among the longest-lived tenth did not grow with dose.^[11] More drug moved the typical mouse, not the ceiling.

What stays open is the step from mouse to person. A gain of 10 to 25 percent on a mouse life of a little over two years.^[11] says nothing certain about the same percentage of a human life. Safety is the second open point, since rapamycin dampens the immune system^[14] and a review found more infections in people with age-related disease who took it^[16] Infections therefore remain a real worry for older users, even at weekly doses. Most off-label users take a low dose once a week, 6 mg being the most common in one survey.^[9] No trial has yet shown, though, that a weekly schedule spares the immune system. Those open points are what the human trials set out to test.

No human trial has shown that rapamycin extends life or healthspan, the years lived in good health. The trials so far are short, and they measure stand-in markers instead of how long people live. The longest placebo-controlled longevity trial of rapamycin published so far (as of October 2026), PEARL, ran for 48 weeks and missed its main goal.^[5] What the trials do show is mostly about safety, and that picture is mixed.

The longevity trials: PEARL and RAPA-EX-01

PEARL gave healthy adults aged 50 to 85 rapamycin at 5 mg or 10 mg a week, or a dummy pill (placebo), for 48 weeks. In the end, 114 people finished it.^[5] It was run by AgelessRx, whose staff wrote the paper and hold shares in the company.^[5] Its main goal was less visceral fat, the deep belly fat around the organs measured on a DEXA scan, and that did not move. The only signals came from secondary measures, outcomes the trial tracked on the side. Women on 10 mg gained lean tissue and reported less pain, but there were only eight of them.^[5] A subgroup that small gives hints, not proof.

PEARL's doses were also lower than they sound. The trial used compounded rapamycin, mixed by a pharmacy instead of the brand-name tablet. By the authors' estimate, its blood levels matched roughly 1.7 and 3.3 mg of the brand-name tablet.^[5] A later analysis by AgelessRx researchers points the same way. A day after dosing, one pharmacy's compounded tablets reached about a third of a generic tablet's blood level, adjusted for dose.^[17] That figure belongs to one product and is no general conversion factor for other compounded tablets.

On safety, side effects in PEARL, including serious ones, were about as common on rapamycin as on placebo, though rapamycin users reported more stomach and gut symptoms.^[5] That result comes from screened volunteers, and the section on talking to a doctor lists who was kept out.^[5]

A smaller trial published in 2026, RAPA-EX-01, tested the dose most common in a user survey, 6 mg a week,^[9] using brand-name tablets.^[15] Its 40 sedentary adults aged 65 to 85 took sirolimus or placebo once a week for 13 weeks, alongside a home exercise programme.^[15] Rapamycin did not improve the exercise gains, and two re-runs limited to those who completed the trial suggested it may even have blunted them slightly. The rapamycin group also reported more adverse events (health problems during a trial, whether or not the drug caused them), 99 against 63, most of them mild. That difference was not statistically significant, but one serious pneumonia was possibly drug-related.^[15] At 13 weeks the trial was far shorter than PEARL, so it adds to the safety picture without settling long-term questions.

The immune trials and RTB101

Before the longevity trials, a series of studies in older adults asked whether gently turning mTOR down could improve immune function. The first used everolimus, a close cousin of rapamycin, and it improved older volunteers' response to a flu vaccine.^[2] A later trial found fewer reported infections over the following year with a low-dose combination of everolimus and an experimental drug called RTB101.^[3] A larger follow-up trial then missed its main goal.^[4] Only a second analysis, which pooled the data, found fewer lab-confirmed respiratory infections on RTB101 10 mg once daily.^[4] The phase 3 trial, which counted symptomatic respiratory illness instead, found no benefit.^[4] That negative result applies to RTB101, not to rapamycin itself.

What transplant patients show

Transplant medicine has the longest experience with sirolimus, but in a very different group. In kidney-transplant patients who had already had a skin cancer, switching to sirolimus meant fewer new squamous-cell skin cancers.^[8] Over two years, 22% of those who switched developed one, against 39% of those who stayed on their old drug.^[8] The price was high, because serious side effects were far more frequent and about 1 in 4 stopped the drug.^[8] An analysis that combined 21 trials also found fewer cancers on sirolimus, but a higher risk of death.^[10] Its authors concluded that the drug is not warranted for most kidney-transplant patients.^[10] These patients already take heavy immune suppression, so neither result maps cleanly onto a healthy adult on a weekly dose.

Side effects at weekly doses

What happens at weekly longevity doses is known mostly from what users report themselves. In an online survey of 333 off-label users and 172 non-users, mouth ulcers were the only problem clearly more common in users.^[9] Infections trended upward as well, but not by enough to be statistically significant.^[9]

For the ulcers there is a lead from cancer care. In patients on the related drug everolimus, a prescription dexamethasone mouth rinse prevented most mouth sores.^[27] That trial had no comparison group, so the result is a hint rather than proof. Whether the rinse makes sense for you is a question for your doctor.

A 2024 review of 19 human studies drew the safety line along health status. It found no serious side effects attributed to rapamycin in healthy people, but more infections and higher blood fats (cholesterol and triglycerides) in people with age-related disease.^[16] The drug label lists further effects, known mostly from transplant patients on daily doses, and how often they happen on weekly low doses is not established.^[14]:

• raised cholesterol and triglycerides, and raised blood sugar
• protein in the urine, which the label asks doctors to check regularly
• slow or impaired wound healing, with a higher risk at a BMI above 30; the label gives no interval for pausing before or after an operation, so tell your surgeon and prescriber early and let them decide
• pneumonitis (inflammation of the lung tissue), which the label lists as common in transplant patients (1 to 10 in 100); a new dry cough or shortness of breath needs urgent checking
• lower blood counts, including the white cells that fight infection
• a higher risk of infections under immune suppression, in transplant patients including serious ones; see a doctor promptly with a fever or an infection that does not clear
• a higher risk of skin cancer under immune suppression, so limit sun and UV exposure
• interactions with many drugs, many of them through the liver and gut enzyme CYP3A4 and the drug pump P-glycoprotein (the list is in the section on talking to a doctor)

Pregnancy, fertility and other reasons not to take it

Several situations rule rapamycin out or need a careful plan with a doctor, and all of them come from the EU label^[14]:

• Pregnancy and breastfeeding. Animal studies showed harm to reproduction, and the risk for humans is unknown, so the EU label says not to use it in pregnancy unless clearly necessary. Effective contraception is required during treatment and for 12 weeks after stopping, and breastfeeding should stop during treatment^[14] No longevity reason justifies it in pregnancy or breastfeeding.
• Contraception. It cannot be ruled out that sirolimus makes the pill less reliable over long-term use.^[14]
• Fertility. In men, sirolimus has impaired sperm quality in some patients, usually reversibly after stopping. In women, ovarian cysts and menstrual disorders have been reported, and ovarian cysts may be more common before menopause than after.^[14]
• Live vaccines (yellow fever, MMR, varicella, nasal flu) should be avoided while you take rapamycin.^[14] Plan them with your doctor well before the first dose, because a short pause in treatment does not automatically make a live vaccine safe. Inactivated vaccines such as flu or COVID shots are allowed but may work less well,^[14] so time them with your doctor.
• Liver disease. The label requires blood-level checks and, if the disease is severe, a lower dose.^[14]
• Surgery, open wounds and active infections. Wound healing slows, so plan any operation with your surgeon and prescriber, and treat an active infection before anything else.

How often the fertility, cyst and contraception effects occur on weekly longevity doses is unknown.

What is still unknown

Three questions stay open for healthy adults: whether rapamycin is safe over ten or more years, which dose and schedule work best, and who, if anyone, benefits. PEARL's 48 weeks are the longest placebo-controlled data so far.^[5] Settling the safety question would take a trial that follows healthy people for years and counts infections, cancers and deaths. Until such a trial exists, anyone who still wants to try rapamycin in Germany needs a legal prescription and a doctor willing to watch the blood work.

Yes, rapamycin can be prescribed legally in Germany, because sirolimus is an approved medicine here. It is approved for only three uses, though, and longevity is not one of them:

• Rapamune tablets: preventing rejection after a kidney transplant.^[6]
• Rapamune tablets: lymphangioleiomyomatosis (LAM), a rare lung disease^[6]
• Hyftor gel (since 2023): facial skin growths (angiofibromas) in tuberous sclerosis complex, a rare genetic disease^[12]

Any prescription for longevity is therefore off-label, meaning a use outside the approval. German doctors may legally write one as a private prescription, but only after careful counselling and with your informed consent. Statutory health insurance does not pay for it, because it covers off-label use only in narrow exceptions and longevity is not one of them^[22] So you get a private prescription and pay yourself.

You can fill that prescription at a German pharmacy. A mail-order pharmacy in another EU or EEA country (the EU plus Iceland, Liechtenstein and Norway) also works, but only if it meets three conditions.^[7][18]:

• it is allowed to ship medicines to customers in Germany
• it supplies a product authorised in Germany
• it follows the German mail-order rules (§73 AMG)

Such pharmacies show the common EU logo on their website^[18]

What it costs

Paying yourself adds up quickly. The cheapest 1 mg pack is an Orifarm parallel import, the same drug brought in from another EU country, at €1,185.61 for 100 tablets.^[13] That puts each milligram at about €11.86.^[13] At 5 to 6 mg a week, that comes to roughly €257 to 308 a month (as of October 2026).^[13] The table shows the cheapest available pack of each strength:

Source: Shop Apotheke product pages, prices read on 21 October 2026.^[13][29][30]

The Pfizer original in 1 mg costs €1,211.46.^[28] Cheaper imports go in and out of stock, so ask the pharmacy what it can supply.

Finding a prescriber

Finding a prescriber is the hard part, because you need a doctor willing to go off-label and very few German practices are. In the US, online longevity clinics prescribe it, while in Germany few if any telemedicine services do. Even an online prescription still needs a real consultation with a doctor, and the section on talking to a doctor covers whom to ask.

The advertising ban

Practices may not advertise rapamycin for longevity, because German law bans that twice over. Prescription drugs may not be advertised to the public at all (§10 HWG).^[21] Advertising a use outside the approval, such as longevity, is banned on top of that (§3a HWG).^[20]

Ordering from outside the EU

Ordering rapamycin by post from outside the EU/EEA, from India or Turkey for example, is banned. The German medicines act (Arzneimittelgesetz, AMG) prohibits mailing prescription medicines from those countries to private individuals in §73.^[7] So this is not a grey zone of the kind the NMN Germany guide deals with. Recipients can face a fine of up to €25,000, because it is an administrative offence under §97 AMG,^[19] and counterfeit drugs can lead to a criminal case.

The one narrow exception is luggage. When entering Germany, a traveller may carry the usual personal supply, which is generally taken to mean up to three months' worth.^[18] That exception does not cover anything sent by post, and a parcel from outside the EU comes without any quality control. The realistic route therefore runs through a German or EU pharmacy and a doctor who will prescribe.

Look for a doctor who has experience monitoring sirolimus or other immunosuppressants and who agrees on regular blood tests and stop rules with you before the first dose. This guide gives no dosing advice. No validated criteria say who should take rapamycin for longevity, so the doctor sets the limits and writes them down with you. Off-label use also needs individual supervision and your informed consent.

Which doctor to ask

There is no German qualification for longevity or prevention medicine,^[23] so a title on the door tells you little. What matters is experience with monitoring sirolimus or other immunosuppressants. Internists are more likely to bring that, and so are doctors with one of these add-on qualifications (German search terms in brackets),^[23]:

• transplant medicine (Transplantationsmedizin)
• immunology (Immunologie)
• geriatrics, the medicine of older age (Geriatrie)
• nutritional medicine (Ernährungsmedizin)

A qualification in naturopathy (Naturheilverfahren) is less likely to come with that experience. Very few German GPs (Hausärzte) write an off-label rapamycin prescription. Dedicated longevity private practices in cities such as Munich, Berlin, Hamburg, Frankfurt, Vienna or Zurich are the more realistic places to ask.

To search, try arzt-auskunft.de with a filter for add-on qualifications (Zusatzbezeichnung), or the directories of the Bavarian medical chamber, the Austrian medical chamber (ÖÄK) or the Swiss FMH. Ask the practice for its fee before the first self-pay (Selbstzahler) visit, and for the cost of lab tests.

Who is probably not a fit

The PEARL trial's exclusion list is a useful starting point for that conversation, because it shows who the researchers kept out^[5]:

• anaemia, or low white-cell (neutropenia) or platelet counts
• major surgery planned in the next 12 months
• chemotherapy, now or planned
• impaired wound healing or a chronic open wound
• untreated high blood fats (lipids)
• impaired liver function
• chronic infections that need ongoing treatment
• a weakened immune system (immune deficiency), or long-term use of oral corticosteroids or other immunosuppressants
• poorly controlled diabetes, type 1 diabetes or insulin-treated type 2 diabetes
• impaired kidney function

PEARL also did not enrol premenopausal women^[5] and the label adds pregnancy, breastfeeding and upcoming live vaccines.^[14]

Drugs that interact

Rapamycin interacts with many drugs, often through the enzyme CYP3A4 and the drug pump P-glycoprotein in the liver and gut.^[14] Anything that blocks them pushes your sirolimus level up, and anything that speeds them up drops it:

• Grapefruit, as juice or as fruit, raises levels.^[14]
• St John's wort and rifampicin (an antibiotic used against tuberculosis) lower levels.^[14]
• Clarithromycin or erythromycin (antibiotics) and ketoconazole or itraconazole (antifungals) raise levels, so avoid them.^[14]
• Diltiazem or verapamil (blood-pressure and heart-rhythm drugs): avoid them, or take them only with blood-level checks and dose changes.^[14]
• ACE inhibitors (for example ramipril or enalapril): together with sirolimus they have caused angioedema, a swelling of the face, tongue or throat.^[14]
• Statins and fibrates were well tolerated together with sirolimus in studies, but the label asks for blood-fat checks and for watching for muscle damage (rhabdomyolysis).^[14]
• Cannabidiol (CBD) can raise sirolimus levels.^[14]

Hand your pharmacist and doctor a full list of what you take, including over-the-counter and herbal products, and tell them before you start or stop anything new.

Lab checks and stop rules

PEARL offers a model for the lab plan. Full blood tests (blood count, blood fats, glucose, kidney and liver values) ran before treatment and at weeks 24 and 48.^[5] Extra safety checks came after 2 and 4 weeks, while HbA1c, a three-month blood-sugar average, was measured only before treatment and at weeks 24 and 48.^[5]

The label adds blood-fat checks and regular urine-protein checks.^[14] Blood levels vary widely between people on the same dose.^[17] That makes a sirolimus blood level worth discussing if your doctor wants one, and always after starting or stopping an interacting drug.^[14][17] Your doctor sets the schedule, and if HbA1c and urine protein are stop criteria, any follow-up should repeat them.

The exact stop limits are also the doctor's to set. Typical reasons to stop or pause are:

• falling white-cell counts
• new protein in the urine
• clearly rising blood fats or HbA1c
• mouth ulcers that do not settle
• any active infection (pause until it clears)

Pregnancy and breastfeeding rule rapamycin out, and effective contraception is required during treatment and for 12 weeks after stopping.^[14] The fertility points for men and women are listed with the other label warnings in the section on human data.

Questions for the first appointment

Before the visit, gather your recent blood results, a full list of your medicines and any current or chronic infections. It also helps to have a clear idea of how much risk you are willing to carry. Then put these questions to the doctor:

1. Do you know the current longevity data on rapamycin?
2. Are you willing to prescribe off-label and document it properly?
3. Which lab values would you track?
4. How often should I come back for check-ins?
5. What would make you stop treatment, and will you put those limits in writing before the first tablet?

A doctor who brushes these questions off is the wrong partner, and so is one who prescribes without asking any questions of their own.